Cervical cancer

Indian Economy glossary

Topic: Human Capital: Education, Health and Demographic Dividend · NCERT: Beyond NCERT

Meaning

Cervical cancer is cancer of the cervix, the lower part of the uterus (womb). Persistent (long-lasting) infection with high-risk types of HPV (human papillomavirus) causes the vast majority of cases. It can be prevented in three ways: a vaccine in girlhood, screening (a test that catches early disease) in adult life, and treatment of early disease.

Why it matters in economics: the disease falls only on women and often hits them in their working years. Vaccination is the "preventive medicine" form of health spending, which is a source of human capital. It protects women's health, their earnings and the savings of their households.

Explanation

How the disease develops and where it can be stopped

  • Cause
  • A girl or woman gets infected with a high-risk type of HPV.
  • If the infection does not clear and stays for years, cells in the cervix can slowly turn into cancer.

  • Three points where the chain can be broken. These match WHO's 90-70-90 targets for 2030. The World Health Assembly adopted them in 2020.

  • Vaccinate (the first "90"): 90% of girls fully vaccinated by age 15. This stops the infection before it starts.
  • Screen (the "70"): 70% of women screened with a high-performance test (one as good as an HPV test) by 35 and again by 45.
  • Treat (the second "90"): 90% of women found with cervical disease get treatment.

  • Why the age of 14

  • The vaccine works best if it is given before likely exposure to HPV. That is why India vaccinates girls at 14.

The vaccine and the single-dose shift

  • HPV vaccines were first licensed for two or three doses.
  • In April 2022, WHO's SAGE (Strategic Advisory Group of Experts on immunisation) found that one dose protects about as well as two.
  • WHO's December 2022 advice allows one or two doses for ages 9-14, and also for girls and young women aged 15-20. WHO calls the single dose an off-label option, meaning it differs from the dosing on the manufacturer's licence.
  • By 10 Sep 2024, 57 countries were using one dose. In Oct 2024, Cecolin became the 4th WHO-prequalified (WHO-approved) HPV vaccine cleared for single-dose use.
  • Why one dose matters economically
  • Each girl needs fewer visits, so cost and logistics fall.
  • The same budget can reach more girls in less time.

  • The open question: vaccines have been used at scale for only about two decades, so nobody yet has 30 years of follow-up on one dose. Vaccinated girls need long-term tracking.

Why vaccination alone cannot meet the 2030 target

  • There is a time lag
  • The girls vaccinated today are 14. Cervical cancer mostly appears in adult women.
  • So the vaccine prevents almost none of the cancers expected by 2030. Today's adult women are protected only by screening and treatment.

  • Worked example: coverage and gaps

  • Annual cohort (all girls born in the same year) ≈ 1.2 crore girls aged 14, based on RGI 2021 estimates.
  • Coverage ≈ 87% → about 13% unvaccinated → 0.13 × 1.2 crore ≈ 15 lakh girls still unvaccinated.
  • Screening: 10.18 crore screened ÷ 25.42 crore eligible women aged 30+ ≈ 40% (as of 20 July 2025). That is well below the "70" target, and it counts screenings of every type.

Cervical cancer as a human capital issue

  • Preventive medicine. Class 11 lists vaccination as the preventive form of health spending, one of the sources of human capital. A one-time vaccine at 14 is a classic preventive investment.
  • Fewer lost working years
  • A sick worker stays away from work, so output is lost.
  • Cervical cancer strikes adult women. It cuts their labour supply and their care of children.

  • Household poverty

  • Cancer treatment can be catastrophic for a family's budget.
  • Out-of-pocket spending (money families pay themselves at the point of care) is about 39% of total health spending (National Health Accounts 2021-22).
  • So every case prevented also protects a family's savings.

  • Market failure

  • Families may not know the risk, or may doubt the vaccine. This information gap means they demand less vaccination than is good for them.
  • That is the case for a free, state-run programme.

In India

  • Programme: the National HPV Vaccination Campaign, run by MoHFW. The PM launched it on 28 Feb 2026 from Ajmer, Rajasthan.
  • Design
  • Free, voluntary and single-dose, for 14-year-old girls, with parental consent.
  • Given at Government health facilities under trained Medical Officers.

  • Safety: the AEFI (Adverse Events Following Immunization) framework, with vaccination sites linked to 24×7 healthcare centres.

  • Digital backbone: U-WIN, the digital vaccination registry, handles real-time monitoring, beneficiary tracking, slot booking and downloadable certificates.
  • Latest figures (Nov 2026)
  • More than 1 crore doses given in under nine months.
  • About 87% coverage of an annual cohort of about 1.2 crore girls (RGI 2021).
  • Six States are at 100%: Gujarat, UP, AP, Mizoram, MP and Bihar.

  • Indigenous vaccine: CERVAVAC is India's first indigenously developed cervical cancer vaccine.

  • UIP status: as of Dec 2024, the HPV vaccine was not part of the Universal Immunization Programme (UIP).
  • Screening
  • Runs through the National NCD Portal under NP-NCD (rolled out 2018), for people aged 30 and above.
  • Delivered at Ayushman Arogya Mandirs (primary care centres).
  • India's main screening test is VIA (visual inspection with acetic acid: a health worker applies a mild acid to the cervix and looks for colour changes).
  • MoHFW reports that an indigenous point-of-care HPV DNA test (done on the spot, without a central lab) has been validated.

  • The screening gap: WHO's India profile (2021) says fewer than 1 in 10 women had been screened in the previous five years.

Don't confuse with

  • HPV infection vs cervical cancer: most HPV infections clear on their own. Only persistent high-risk HPV infection leads to cervical cancer.
  • Vaccination (primary prevention) vs screening (secondary prevention): the vaccine stops infection in girls before exposure. Screening finds early disease in adult women aged 30 and above. Only screening and treatment can lower cases before 2030.
  • Doses vs coverage: "1 crore" counts doses given. "About 87%" is the share of the annual cohort covered. Coverage is measured against an RGI estimate, not a headcount.
  • WHO 90-70-90 vs Indonesia 90-75-90: 90-70-90 is WHO's global target for 2030. 90-75-90 is Indonesia's own national version.

Prelims Hooks

  • Persistent infection with high-risk HPV types causes the vast majority of cervical cancer cases.
  • India's campaign: single dose, 14-year-old girls, free and voluntary, parental consent, launched 28 Feb 2026 from Ajmer, run by MoHFW. U-WIN is the digital platform.
  • WHO's 90-70-90 targets for 2030, adopted by the WHA in 2020: 90% of girls vaccinated by age 15, 70% of women screened by 35 and 45, 90% treated.
  • SAGE (April 2022): one dose gives protection comparable to two. Trap: "India's campaign uses a 2-dose schedule for girls aged 9-14": FALSE.
  • CERVAVAC is India's first indigenous cervical cancer vaccine. As of Dec 2024, the HPV vaccine was outside the UIP.
  • Screening runs through NP-NCD / National NCD Portal (2018) for people aged 30 and above. Trap: VIA, India's main test, does not count as WHO's "high-performance test".

Mains Points

  • Prevention as human capital investment
  • A low-cost single dose at 14 → fewer cancers in women of working age → less lost labour and less catastrophic out-of-pocket spending (about 39% of health spending, NHA 2021-22).
  • Vaccination has external benefits: it also reduces the spread of HPV to others. Markets undersupply goods with external benefits, so free state provision is justified.

  • The vaccine helps only in the long run; screening is the 2030 gap

  • Today's adult women depend on screening, which reaches only about 40% of eligible women on the NCD Portal count (July 2025), and fewer than 1 in 10 on WHO's five-year measure.
  • Possible steps:

    • move from VIA to indigenous HPV DNA tests;
    • add HPV to the UIP so funding is permanent;
    • run a catch-up drive for girls aged 15-20, which WHO's 2022 advice allows;
    • link U-WIN records to the NCD Portal, so vaccinated girls are called for screening at 30.
  • Equity and federal delivery

  • The Union, States and districts deliver the campaign together, and earlier programmes in Bihar, Tamil Nadu and Sikkim were merged into it.
  • Coverage still varies by State, so lagging States need targeted catch-up.
  • Consent and misinformation are real barriers. ASHAs, ANMs and teachers are used to build parents' trust.

Read more